DrugCentral
Up to date resource on currently approved FDA drugs , drugs approved worldwide, and discontinued drugs. Integrates knowledge on drug active ingredients chemical structure, pharmaceutical products (FDA), indications, pharmacological action, bioactivity profile, and mechanism of action. Find the web app and other resources at DrugCentral.org.
New RAG Chatbot Conversational Access
DrugCentral introduces a retrieval-augmented generation (RAG) chatbot that allows users to explore drug information through natural-language questions. The chatbot retrieves relevant information from DrugCentral and generates contextual responses about drug properties, therapeutic indications, biological targets, and pharmacological relationships, providing a more accessible way to interact with the database.
New Predicted Properties from AstraZeneca Models
DrugCentral incorporates computational predictions generated using AstraZeneca models to expand the available information on drug properties. These predictions complement experimentally established data and provide additional insights that may support drug characterization, computational analysis, and drug discovery research.
New DrugRepoDb, Clinical Trials Driven Repurposing Tool
DrugCentral introduces DrugRepoDb, a clinical trials-driven drug repurposing resource designed to support the identification and investigation of potential new therapeutic uses for existing drugs. By integrating information from clinical trials, DrugRepoDb helps researchers explore drug-disease relationships and evaluate opportunities for drug repositioning.
New Code Improvements, API, Docker-ization, Modernized DevOps
DrugCentral includes improvements to its software architecture, application programming interfaces (APIs), containerization, and deployment infrastructure. Updated code, Docker-based deployment, and modernized DevOps workflows improve maintainability, reproducibility, scalability, and accessibility for researchers and developers integrating DrugCentral into their applications.